Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.47M | 3.22M | 3.13M | 3.75M | 7.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.47M | 3.22M | 3.13M | 3.75M | 7.53M |
| Cost of Revenue | 339.41M | 330.76M | 328.68M | 332.27M | 330.12M |
| Gross Profit | -320.93M | -327.54M | -325.54M | -328.52M | -322.59M |
| SG&A Expenses | 215.31M | 197.09M | 180.55M | 169.45M | 173.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 554.72M | 527.85M | 509.22M | 501.72M | 503.74M |
| Operating Income | -536.25M | -524.63M | -506.09M | -497.97M | -496.21M |
| Income Before Tax | -589.53M | -576.40M | -545.28M | -530.60M | -526.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -589.53 | -576.40 | -545.28 | -530.60 | -526.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -589.53M | -576.40M | -545.28M | -530.60M | -526.24M |
| EBIT | -536.25M | -524.63M | -506.09M | -497.97M | -496.21M |
| EBITDA | -526.72M | -511.14M | -493.16M | -485.59M | -484.31M |
| EPS Basic | -5.28 | -5.39 | -5.37 | -5.40 | -5.45 |
| Normalized Basic EPS | -3.30 | -3.37 | -3.36 | -3.38 | -3.41 |
| EPS Diluted | -5.28 | -5.39 | -5.37 | -5.40 | -5.45 |
| Normalized Diluted EPS | -3.30 | -3.37 | -3.36 | -3.38 | -3.41 |
| Average Basic Shares Outstanding | 446.92M | 427.92M | 406.30M | 392.82M | 386.06M |
| Average Diluted Shares Outstanding | 446.92M | 427.92M | 406.30M | 392.82M | 386.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
